Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apn

Fujian Shengdi Pharmaceutical Co · Phase 3 · Active, not recruiting · Enrollment 144

NCT06994650

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
HRS9531n/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • HRS9531: endpoint not reported
  • Placebo: endpoint not reported